Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.58 |
| ▸ | MTOR | P42345 | 15/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923596 | 0.93 | PIK3CA (0.50) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL3929252 | 0.91 | PIK3CA (0.62) | PIK3CAPIK3CDMTOR | |
| SCHEMBL3935222 | 0.90 | PIK3CA (0.47) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL3927064 | 0.85 | MTOR (0.55) | PIK3CAPIK3CDMTOR | |
| SCHEMBL3926913 | 0.84 | PIK3CA (0.53) | PIK3CAPIK3CDMTOR | |
| SCHEMBL3935715 | 0.84 | MTOR (0.63) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL3926487 | 0.84 | SMN1; SMN2 (0.42) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL3924111 | 0.83 | PIK3CA (0.55) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL3926690 | 0.83 | MTOR (0.57) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL3926434 | 0.82 | MTOR (0.53) | PIK3CAPIK3CDMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074118-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |